Lipoprotein-Associated Phospholipase A 2 , High-Sensitivity C-Reactive Protein , and Risk for Incident Coronary Heart Disease in Middle-Aged Men and Women in the Atherosclerosis Risk in Communities ( ARIC ) Study

No abstract is available for this paper.

• Publication year

  2004

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins Published, JLR Papers in Press, March 1, 2003. DOI 10.1194/jlr.M200452-JLR200

  2003cited by this paper
• Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.

  2003cited by this paper
• MARKERS OF INFLAMMATION AND CARDIOVASCULAR DISEASE: APPLICATION TO CLINICAL AND PUBLIC HEALTH PRACTICE: A STATEMENT FOR HEALTHCARE PROFESSIONALS FROM THE CENTERS FOR DISEASE CONTROL AND PREVENTION AND THE AMERICAN HEART ASSOCIATION

  2003cited by this paper
• The Discovery of SB-435495: A Potent, Orally Active Inhibitor of Lipoprotein-Associated Phospholipase A2 for Evaluation in Man.

  2003cited by this paper
• Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events*

  2002cited by this paper
• Atorvastatin Preferentially Reduces LDL-Associated Platelet-Activating Factor Acetylhydrolase Activity in Dyslipidemias of Type IIA and Type IIB

  2002cited by this paper
• C-reactive protein and incident coronary heart disease in the Atherosclerosis Risk In Communities (ARIC) study.

  2002cited by this paper
• C-reactive protein binds to both oxidized LDL and apoptotic cells through recognition of a common ligand: Phosphorylcholine of oxidized phospholipids

  2002cited by this paper
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial.

  2002cited by this paper
• Lp-PLA2: an emerging biomarker of coronary heart disease

  2002cited by this paper
• Inflammatory biomarkers, hormone replacement therapy, and incident coronary heart disease: prospective analysis from the Women's Health Initiative observational study.

  2002cited by this paper
• A prospective evaluation of lipoprotein-associated phospholipase A(2) levels and the risk of future cardiovascular events in women.

  2001cited by this paper
• Improving coronary heart disease risk assessment in asymptomatic people: role of traditional risk factors and noninvasive cardiovascular tests.

  2001cited by this paper
• Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events.

  2001cited by this paper
• Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2.

  2001cited by this paper
• Baseline Characteristics of Participants in the Women's Health Study

  2000cited by this paper
• PREVENTION OF CORONARY HEART DISEASE WITH PRAVASTATIN IN MEN WITH HYPERCHOLESTEROLEMIA

  2000cited by this paper
• Direct Proinflammatory Effect of C-Reactive Protein on Human Endothelial Cells

  2000cited by this paper
• Platelet-activating factor acetylhydrolases in health and disease.

  2000cited by this paper
• Analysis of case-cohort designs.

  1999cited by this paper
• C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction.

  1998cited by this paper
• The sixth report of the Joint National Committee on the Detection, Evaluation, and Treatment of High Blood Pressure

  1998cited by this paper
• Circulating adhesion molecules VCAM-1, ICAM-1, and E-selectin in carotid atherosclerosis and incident coronary heart disease cases: the Atherosclerosis Risk In Communities (ARIC) study.

  1997cited by this paper
• Influence of plasma lipid and LDL-subfraction profile on the interaction between low density lipoprotein with human arterial wall proteoglycans.

  1996cited by this paper
• Range of serum cholesterol values in the population developing coronary artery disease.

  1995cited by this paper
• Robust variance estimation for the case-cohort design.

  1994cited by this paper
• Distribution of PAF-acetylhydrolase activity in human plasma low-density lipoprotein subfractions.

  1994cited by this paper
• Association of hemostatic variables with prevalent cardiovascular disease and asymptomatic carotid artery atherosclerosis. The Atherosclerosis Risk in Communities (ARIC) Study Investigators.

  1993cited by this paper
• Plasma lipid, lipoprotein cholesterol, and apoprotein distributions in selected US communities. The Atherosclerosis Risk in Communities (ARIC) Study.

  1993cited by this paper
• Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects.

  1991cited by this paper
• The Atherosclerosis Risk in Communities (ARIC) Study: design and objectives. The ARIC investigators.

  1989cited by this paper
• A case-cohort design for epidemiologic cohort studies and disease prevention trials

  1986cited by this paper

• The precise role of Lipoprotein associated phospholipase A2 (Lp-PlA2) in the pathogenesis of acute coronary syndromes

  2023cites this paper
• Cardiovascular Disease and Alzheimer's Disease: The Heart–Brain Axis

  2023cites this paper
• Novel Biomarkers of Atherosclerotic Vascular Disease—Latest Insights in the Research Field

  2022cites this paper
• Sensitivity, specificity of biochemical markers for early prediction of endothelial dysfunction in atherosclerotic obese subjects

  2022cites this paper
• Hs-CRP as an important inflammatory risk marker of CAD in diabetes mellitus patients

  2021cites this paper
• Discrimination is associated with C-reactive protein among young sexual minority men

  2021cites this paper
• Estimating the hazard rate difference from case-cohort studies

  2021cites this paper
• The use of blood biomarkers in precision medicine for the primary prevention of atherosclerotic cardiovascular disease: a review

  2021cites this paper
• Role of phospholipase C in banana in response to anthracnose infection

  2020cites this paper
• Contribution of Non Traditional Cardiovascular Risk Factors to the Cardiovascular Disease in Patient with Type 2 Diabetes

  2020cites this paper
• Lipoprotein-associated phospholipase A2 activity, genetics and calcific aortic valve stenosis in humans

  2020cites this paper
• Metabolomic Pattern Predicts Incident Coronary Heart Disease.

  2019cites this paper
• Association Between Systemic Inflammation, Carotid Arteriosclerosis, and Autonomic Dysfunction

  2019cites this paper
• High-Sensitivity Troponin I and Incident Coronary Events, Stroke, Heart Failure Hospitalization, and Mortality in the ARIC Study.

  2019cites this paper
• C-reactive protein levels as a cardiovascular risk factor in patients with and without periodontal disease who are undergoing hip and/or knee arthroplasty

  2018cites this paper
• Association between high‐sensitivity C‐reactive protein, lipoprotein‐associated phospholipase A2 and carotid atherosclerosis: A cross‐sectional study

  2018cites this paper
• The Prognostic Value of Lipoprotein-Associated Phospholipase A2 in the Long-Term Care of Patients With Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention

  2017cites this paper
• A regularized variable selection procedure in additive hazards model with stratified case-cohort design

  2017cites this paper
• Lipoprotein-associated phospholipase A2 and risks of coronary heart disease and ischemic stroke in the general population: A systematic review and meta-analysis.

  2017cites this paper
• PM303 Can C-Reactive Protein and Fibrinogen Predict Major Adverse Cardiac Events in Cardiovascular and Cerebrovascular Patients?

  2016cites this paper
• Lipoprotein-associated phospholipase A2 prognostic role in atherosclerotic complications.

  2015cites this paper
• Testosterone and high‐sensitive C‐reactive protein in coronary artery disease patients awaiting coronary artery bypass graft

  2015cites this paper
• STABILITY and SOLID-TIMI 52: Lipoprotein associated phospholipase A2 (Lp-PLA2) as a biomarker or risk factor for cardiovascular diseases

  2015cites this paper
• C-reactive protein and lipoprotein-associated phospholipase A2 in smokers and nonsmokers of the Ludwigshafen Risk and Cardiovascular Health study.

  2015cites this paper
• Overview of PAF-Degrading Enzymes.

  2015cites this paper
• Increased serum level of Lp-PLA2 is independently associated with the severity of coronary artery diseases: a cross-sectional study of Chinese population

  2015cites this paper
• Alimentation et inflammation : considérations épidémiologiques, cliniques et métaboliques

  2015cites this paper
• Pathogenesis, prevention and treatment of peripheral artery disease

  2014cites this paper
• Increased plasma level of soluble urokinase plasminogen activator receptor is associated with incidence of heart failure but not atrial fibrillation

  2014cites this paper
• Additive hazards risk prediction using a stratified cohort random sample : Secondary analysis of data from an ARIC study of CHD and hs-CRP

  2014cites this paper
• Association between the lipoprotein-associated phospholipase A2 activity and the progression of subclinical atherosclerosis.

  2014cites this paper
• Lipoprotein-associated phospholipase A2 regulates macrophage apoptosis via the Akt and caspase-7 pathways.

  2014cites this paper
• Lipoprotein‐associated phospholipase A2 and cardiovascular disease risk in HIV infection

  2014cites this paper
• Lipoprotein-Associated Phospholipase A 2 , a Novel Cardiovascular In fl ammatory Marker , in HIV-Infected Patients

  2014cites this paper
• Effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity in Japanese dyslipidemic patients, with exploratory analysis of a PLA2G7 gene polymorphism of Val279Phe.

  2013cites this paper
• Marginal additive hazards model for case-cohort studies with multiple disease outcomes: an application to the Atherosclerosis Risk in Communities (ARIC) study.

  2013cites this paper
• RELEVANCE OF ACHIEVED LEVELS OF MARKERS OF SYSTEMIC INFLAMMATION FOLLOWING TREATMENT RELEVANZ ERZIELTER NIVEAUS VON MARKERN FÜR SYSTEMISCHE ENTZÜNDUNG NACH BEHANDLUNG PERTINENCE DE NIVEAUX OBTENUS DE MARQUEURS D’INFLAMMATION GENERALISEE ALA SUITE D’UN TRAITEMENT

  2013cites this paper
• Lipoprotein-associated phospholipase A2 and venous thromboembolism: a prospective study.

  2013cites this paper
• Icosapent Ethyl, a Pure Ethyl Ester of Eicosapentaenoic Acid: Effects on Circulating Markers of Inflammation from the MARINE and ANCHOR Studies

  2013cites this paper
• Correlation between plasma lipoprotein-associated phospholipase A2 and peripheral arterial disease

  2013cites this paper
• Lipoprotein-Associated Phospholipase A2 (Lp-PLA2): A Novel and Promising Biomarker for Cardiovascular Risks Assessment

  2013cites this paper
• Lipoprotein-associated Phospholipase A2 and Serum Lipid Levels in Subjects with Chronic Periodontitis and Hyperlipidaemia

  2012cites this paper
• Normal levels of inflammatory markers in treated patients with familial hypercholesterolaemia: a cross-sectional study

  2012cites this paper
• C-Reactive Protein Predicts the Severity of Coronary Artery Disease Beyond Low-Density Lipoprotein Cholesterol

  2012cites this paper
• Translational studies of lipoprotein-associated phospholipase A₂ in inflammation and atherosclerosis.

  2012cites this paper
• Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk.

  2012cites this paper
• Usefulness of high-sensitivity C-reactive protein to predict mortality in patients with atrial fibrillation (from the Atherosclerosis Risk In Communities [ARIC] Study).

  2012cites this paper
• Eight genetic loci associated with variation in lipoprotein-associated phospholipase A2 mass and activity and coronary heart disease: meta-analysis of genome-wide association studies from five community-based studies.

  2012cites this paper
• Comparison of Effects of Morning Versus Evening Administration of Ezetimibe/Simvastatin on Serum Cholesterol in Patients with Primary Hypercholesterolemia

  2011cites this paper
• Bioactive lipids in atherosclerosis

  2011cites this paper
• Kidney Function Decline in the Elderly: Impact of Lipoprotein-Associated Phospholipase A2

  2011cites this paper
• Effect of Periodontal Treatment on Lipoproteins Levels in Plasma in Patients with Periodontitis

  2011cites this paper
• Systematic Review of the Association between Lipoprotein-Associated Phospholipase A2 and Atherosclerosis.

  2011cites this paper
• The role of inflammation in heart failure: new therapeutic approaches.

  2011cites this paper
• Lp-PLA2 Inhibition—The Atherosclerosis Panacea?

  2010cites this paper
• Lipoprotein-associated phospholipase A2, C-reactive protein, and coronary artery disease in individuals with type 1 diabetes and macroalbuminuria

  2010cites this paper
• Should We Measure C‐reactive Protein on Earth or Just on JUPITER?

  2010cites this paper
• Phospholipase A2 as a therapeutic target for atherosclerosis

  2010cites this paper
• Variability of C-reactive protein levels among patients with stable coronary artery disease and on statin therapy.

  2009cites this paper
• Emerging Risk Factors for Coronary Heart Disease: A Summary of Systematic Reviews Conducted for the U.S. Preventive Services Task Force

  2009cites this paper
• Myocardial infarction patients show altered lipoprotein properties and functions when compared with stable angina pectoris patients

  2009cites this paper
• Lipoprotein-Associated Phospholipase A2 and High-Sensitivity C-Reactive Protein Improve the Stratification of Ischemic Stroke Risk in the Atherosclerosis Risk in Communities (ARIC) Study

  2009cites this paper
• C-Reactive Protein as a Risk Factor for Coronary Heart Disease: A Systematic Review and Meta-analyses for the U.S. Preventive Services Task Force

  2009influential citation
• Clinical and genetic factors associated with lipoprotein-associated phospholipase A2 in the Framingham Heart Study.

  2009cites this paper
• Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target

  2009cites this paper
• Hepatic nuclear factor 1-α: inflammation, genetics, and atherosclerosis

  2009cites this paper
• Simvastatin Reduces Expression and Activity of Lipoprotein-Associated Phospholipase A2 in the Aorta of Hypercholesterolaemic Atherosclerotic Rabbits

  2009cites this paper
• New insights in preventive cardiology and cardiac rehabilitation

  2008cites this paper
• Lipoprotein-Associated Phospholipase A2 Activity and Risk of Recurrent Stroke

  2008cites this paper
• The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.

  2008cites this paper
• Comprehensive genetic analysis of the platelet activating factor acetylhydrolase (PLA2G7) gene and cardiovascular disease in case-control and family datasets.

  2008cites this paper
• Lipoprotein‐associated phospholipase A2 and risk of venous thrombosis in older adults

  2008cites this paper
• Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

  2008cites this paper
• Effect of paraoxonase 1 polymorphisms on the response of lipids and lipoprotein-associated enzymes to treatment with fluvastatin.

  2007cites this paper
• C-Reactive Protein and Cardiovascular Risk in the Metabolic Syndrome and Type 2 Diabetes: Controversy and Challenge

  2007cites this paper
• Biochemical and bioimaging markers for risk assessment and diagnosis in major cardiovascular diseases: a road to integration of complementary diagnostic tools

  2007cites this paper
• Impact of atorvastatin treatment on platelet-activating factor acetylhydrolase and 15-F(2trans)-isoprostane in hypercholesterolaemic patients.

  2007cites this paper
• Association of Lipoprotein-associated Phospholipase A2 with Coronary Calcification among American and Japanese Men

  2007cites this paper
• Lipoprotein-associated phospholipase A2: a new biomarker for cardiovascular risk assessment and potential therapeutic target

  2007cites this paper
• Inflammation and ischaemic stroke

  2007cites this paper
• Expression and purification of lipoprotein-associated phospholipase A2, a key enzyme involved in atherosclerosis

  2006cites this paper
• Lipid metabolism.

  2006cites this paper
• Inflammation, Atherosclerosis, and Stroke

  2006cites this paper
• Roles of nuclear cardiology, cardiac computed tomography, and cardiac magnetic resonance: Noninvasive risk stratification and a conceptual framework for the selection of noninvasive imaging tests in patients with known or suspected coronary artery disease.

  2006cites this paper
• Lipoprotein-Associated Phospholipase A2 Predicts Future Cardiovascular Events in Patients With Coronary Heart Disease Independently of Traditional Risk Factors, Markers of Inflammation, Renal Function, and Hemodynamic Stress

  2006cites this paper
• The Effect of Including C-Reactive Protein in Cardiovascular Risk Prediction Models for Women

  2006cites this paper
• Phospholipid mediators in the vessel wall: involvement in atherosclerosis

  2005cites this paper
• Systemic Low-Grade Inflammation and Risk of Coronary Heart Disease: Results from the MONICA/KORA Augsburg Cohort Studies

  2005cites this paper
• Preventing ischemic stroke: choosing the best strategy.

  2005cites this paper
• Systemic low-grade inflammation and risk of coronary heart disease: results from the MONICA/KORA Augsburg cohort studies.

  2005cites this paper
• Lipoprotein-associated phospholipase A2 as a target of therapy

  2005cites this paper
• Role of intravascular ultrasound in the evaluation of therapeutic interventions in coronary atherosclerosis Related review: Role of CETP inhibitors in the treatment of dyslipidemia (pp 631–636)

  2004cites this paper
• Established and emerging plasma biomarkers in the prediction of first atherothrombotic events.

  2004cites this paper
• Should C-reactive protein be added to metabolic syndrome and to assessment of global cardiovascular risk?

  2004cites this paper
• Lipoprotein-Associated Phospholipase A 2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population

  2004cites this paper
• Lipoprotein-Associated Phospholipase A2 Adds to Risk Prediction of Incident Coronary Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Population: Results From the 14-Year Follow-Up of a Large Cohort From Southern Germany

  2004cites this paper
• Increased plasma non-esterified fatty acids and platelet-activating factor acetylhydrolase are associated with susceptibility to atherosclerosis in mice.

  2004cites this paper
• Germany Population : Results From the 14-Year Follow-Up of a Large Cohort From Southern Events by C-Reactive Protein in Apparently Healthy Middle-Aged Men From the General Adds to Risk Prediction of Incident Coronary 2 Lipoprotein-Associated Phospholipase

  2004cites this paper
• Introduction – cardiac biomarkers and diagnostics

  year unknowncites this paper